LifeSplice was awarded an NIH R21 grant for the initial development of SMOs to alter the expression of RAGE isoforms implicated in the pathogenesis of Alzheimer’s Disease (AD). AD is a severe neurodegenerative disorder characterized by progressive memory loss, language deficits, personality changes, and dementia, most prevalent in patients over 65. Current treatments only have modest and temporary effects on cognitive decline, highlighting the need for novel treatments that can halt the progression of AD. RAGE is important to several AD-related pathways, including accumulation of amyloid-beta (Aβ) plaques, hyper-phosphorylated tau neurofibrillary tangles (NTs), and severe gliosis, making it a prime therapeutic target.